Vigil Neuroscience, Inc. (VIGL)

2.7100 +0.1300 (+5.04%) At close: 04:00PM EDT

Vigil Neuroscience, Inc.

100 Forge Road
Suite 700 Watertown
Watertown, MA 02472
United States
857 254 4445
https://www.vigilneuro.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 69

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.	President, CEO & Director	908.25k	N/A	1967
Sharon Morani	Senior Director of Facilities & Operations	N/A	N/A	N/A
Dr. David Gray Ph.D.	Chief Scientific Officer	N/A	N/A	1975
Ms. Leah Gibson	Vice President of Investor Relations and Corporate Communications	N/A	N/A	N/A
Mr. Christopher Verni J.D.	General Counsel & Corporate Secretary	N/A	N/A	1975
April Effort M.B.A., M.S.	VP & Head of Corporate Development	N/A	N/A	N/A
Mr. Evan A. Thackaberry DABT, Ph.D.	Senior VP & Head of Early Development	N/A	N/A	1973
Christian Mirescu Ph.D.	VP & Head of Neuroimmunology	N/A	N/A	N/A
Weeteck Yeo Ph.D.	Senior Vice President of Strategic Operations	N/A	N/A	N/A
Andreas Meier M.D.	Senior Vice President of Clinical & Medical Sciences	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Corporate governance

Vigil Neuroscience, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.